

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (date of earliest event reported):
September 23, 2002

HARVARD BIOSCIENCE, INC.
(Exact Name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

0-31923
(Commission File
Number)

04-3306140
(I.R.S. Employer
Identification No.)

84 October Hill Road, Holliston, MA 01746-1371
(Address of principal executive offices and zip code)

(508) 893-8999
(Registrant's telephone number, including area code)

This Current Report on Form 8-K may contain forward-looking statements within the meaning of the federal securities laws. Reliance should not be placed on forward-looking statements because they involve known and unknown risks and uncertainties which may cause the actual results, performance, and achievements of the Company to differ materially from the anticipated future results, performance and achievements that are expressed or implied by such forward-looking statements. Additional information concerning these risks and uncertainties is contained in the section entitled "Important Factors That May Affect Future Operating Results" of the Company's Annual Report on Form 10-K for the year ended December 31, 2001. The Company disclaims any obligation to update any of the forward-looking statements contained herein to reflect future developments or events.

ITEM 5. OTHER EVENTS

On September 23, 2002, Harvard Bioscience, Inc. filed a prospectus supplement to its prospectus dated September 17, 2002 pursuant to Rule 424(b)(3) and (c) under the Securities Act of 1933. The prospectus supplement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

(a) Financial Statements of the Business Acquired.

Not applicable.

(b) Pro Forma Financial Information.

Not applicable.

(c) Exhibits.

99.1 Prospectus Supplement dated September 23, 2002 to
Prospectus dated September 17, 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 23, 2002

HARVARD BIOSCIENCE, INC.

By: /s/ David Green

David Green
President

3

EXHIBIT INDEX

99.1 Prospectus Supplement dated September 23, 2002 to Prospectus dated September 17, 2002.

4

Filed Pursuant to
Rule 424(b)(3) and (c)
File No. 333-98927

PROSPECTUS SUPPLEMENT DATED SEPTEMBER 23, 2002
TO PROSPECTUS DATED SEPTEMBER 17, 2002

After the close of business on September 17, 2002, Harvard Bioscience, Inc. announced new financial guidance for the fiscal year ended December 31, 2002. In the announcement, Harvard Bioscience revised downward its previously announced guidance due to the continued slower than expected adoption of its COPAS (TM) technology and unexpected weakness in its international business in the third quarter.

Harvard Bioscience common stock is traded on the Nasdaq National Market under the trading symbol "HBIO" and on September 20, 2002, the closing price of Harvard Bioscience common stock was \$2.82 per share. Consequently, based on this price, applying an assumed conversion ratio as of September 20, 2002 of 0.1016 of a share of Harvard Bioscience common stock and \$0.2858 in cash for each share of Genomic Solutions common stock, the equivalent price per share of Genomic Solutions common stock on September 20, 2002 was \$0.5723. This amount is an estimate based on the number of outstanding shares of Genomic Solutions common stock on September 20, 2002, and assuming that all in-the-money options to purchase Genomic Solutions common stock outstanding on September 20, 2002 are exercised prior to the merger and may change at the completion of the merger as a result of changes in the number of shares of Genomic Solutions common stock outstanding due to, among other things, actual stock option exercises and purchases under the Genomic Solutions employee stock purchase plan.

Because the market price of Harvard Bioscience common stock may increase or decrease before the completion of the merger, you are urged to obtain current market quotations.

You are encouraged to read and consider carefully the discussion in the section entitled "Risk Factors" beginning on page 21 of the proxy statement and prospectus to which this supplement relates.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE MERGER OR THE SHARES OF HARVARD BIOSCIENCE COMMON STOCK TO BE ISSUED IN THE MERGER, OR DETERMINED IF THE PROXY STATEMENT AND PROSPECTUS IS ACCURATE OR ADEQUATE. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.